J. Safra Sarasin Holding AG Has $6.84 Million Holdings in Boston Scientific Corporation $BSX

J. Safra Sarasin Holding AG decreased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 59.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 109,029 shares of the medical equipment provider’s stock after selling 161,436 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Boston Scientific were worth $6,840,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Renaissance Group LLC acquired a new position in Boston Scientific during the 4th quarter worth approximately $28,064,000. Rathbones Group PLC grew its stake in Boston Scientific by 20.9% in the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after acquiring an additional 477,680 shares during the period. Tounjian Advisory Partners LLC bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $1,477,000. Waycross Partners LLC bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $2,384,000. Finally, Union Bancaire Privee UBP SA raised its position in shares of Boston Scientific by 15.0% during the fourth quarter. Union Bancaire Privee UBP SA now owns 248,497 shares of the medical equipment provider’s stock worth $23,417,000 after purchasing an additional 32,425 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $44.65 on Tuesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The firm has a 50-day moving average of $49.15 and a 200-day moving average of $67.13. Boston Scientific Corporation has a one year low of $42.25 and a one year high of $109.50. The company has a market cap of $66.36 billion, a P/E ratio of 18.68, a P/E/G ratio of 0.86 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the previous year, the company earned $0.75 earnings per share. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its board has approved a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of recent research reports. Wells Fargo & Company reiterated an “equal weight” rating and issued a $55.00 target price (down from $75.00) on shares of Boston Scientific in a report on Thursday, May 28th. Oppenheimer set a $90.00 price objective on shares of Boston Scientific in a research note on Thursday, April 23rd. Jefferies Financial Group decreased their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Zacks Research lowered shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Finally, Stifel Nicolaus dropped their price target on shares of Boston Scientific from $75.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $80.72.

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the transaction, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 9,800 shares of company stock valued at $554,012 in the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.